{
    "nct_id": "NCT05519111",
    "official_title": "Dronabinol for the Reduction of Chronic Pain and Inflammation in People With Sickle Cell Disease",
    "inclusion_criteria": "* Age >18 years\n* Clinical diagnosis of SCD (HbSS, HbSC, HbSβ+; Thal, HbSβ0Thal, HbS variants)\n* Baseline score of 60 or lower on the ASCQ-Me 7-day pain interference domain\n* If on a SCD modifying therapy (hydroxyurea, regular blood transfusions, L-glutamine, voxelotor, crizanlizumab), on stable dose for at least 3 months\n* If using opioids for pain at home, on stable dose for at least 3 months\n* One urine toxicology negative for cannabinoids within 30 days of randomization\n* No known intolerance to dronabinol, or marijuana\n* No history of psychotic episode, psychosis, or active suicidality\n* No contraindication to dronabinol with attention to potential side effects, concurrent medications/substances, and concurrent medical problems, as evaluated by a physician\n* Willing to abstain from cannabis, medical and illicit, during study weeks 1 through 8\n* Not pregnant or nursing\n* If a woman capable of becoming pregnant, willing to use a medically accepted form of birth control for the duration of study participation. Accepted forms include oral contraception, medroxyprogesterone, contraceptive implants or patch, surgical sterilization, total abstinence.\n* Able to consent for research\n* No daily cannabis use\n* No diagnosis of active substance use disorder\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}